Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

Cagrilintide: sourcing, documentation and price

Cagrilintide is a long-acting amylin receptor agonist studied as a monotherapy and in fixed-dose combination with semaglutide. This page covers its identifiers, the research record across animal and human models, and wha

peptides-pro Editorial

Cagrilintide is a long-acting amylin receptor agonist developed as a once-weekly subcutaneous therapy for weight management, both as a monotherapy and as a fixed-dose combination with the GLP-1 receptor agonist semaglutide (CagriSema) [4]. It is a synthetic peptide analogue; the evidence block for this page does not supply a sequence, molecular formula or molecular weight, so those identifiers are not reproduced here. The compound is not prescribable and remains under clinical development [1].

The work around cagrilintide centres on the amylin receptor, a heterodimeric complex of the calcitonin receptor (Calcr) and a receptor-activity-modifying protein, with Ramp3 identified in area postrema neurons in the cross-species atlas described below [3].

Research Studies

Cagrilintide and the dorsal vagal complex in rat, mouse and macaque

A transcriptomic atlas of more than 530,000 cells, covering 80 neuronal cell populations across rat, mouse and macaque caudal brainstem, was generated with spatial profiling to map distribution in the rat dorsal vagal complex (DVC) [3]. The authors reported that cagrilintide regulates two conserved Calcr-expressing DVC neuronal populations. Acute treatment altered gene expression in area postrema Calcr/Ramp3 neurons, but chemogenetic activation of those neurons in rats did not affect long-term food intake or body weight. Long-term cagrilintide treatment in rats produced a different response pattern in the DVC [3]. This work is animal and cross-species tissue work; it does not establish human outcomes.

Cagrilintide and renal or hepatic impairment in adult participants

Two studies assessed the effect of renal or hepatic impairment on pharmacokinetics, safety and tolerability after single doses of cagrilintide [4]. Adult participants were categorised into four groups by renal or hepatic function — normal function and mild, moderate or severe impairment — and received a single dose of cagrilintide 0.6 or 0.9 (units as reported in the source) [4]. The report concluded that renal or hepatic impairment did not affect the pharmacokinetics, safety or tolerability of subcutaneous cagrilintide [4].

Cagrilintide and tolerability in participants not tolerating GLP-1 receptor agonists

A clinical study is examining the safety of cagrilintide compared with placebo in people who do not tolerate marketed GLP-1 therapies and who live with overweight or obesity [5]. Participants receive cagrilintide or placebo, allocated by chance, and the study runs for about 8 months [5]. This is a registered study record; results are not reported in the evidence block.

Cagrilintide and food intake and appetite in people with overweight or obesity

A separate study is testing cagrilintide to understand how it affects food intake and appetite in people with overweight or obesity [8]. Participants receive cagrilintide or placebo, allocated by chance, over a study period of about 30 weeks [8]. As above, this is a study record rather than a results report.

Cagrilintide and formulation comparisons: versions B and D

Several registered studies compare different versions of injectable cagrilintide. One compares two versions, cagrilintide B and cagrilintide D, in adults with excess body weight over about 14 weeks [6]. Another compares blood levels after multiple doses of the two versions in adults with overweight or obesity over about 6 months [7]. A further study compares two different versions of injectable cagrilintide and placebo in people with excess body weight, with a study duration of about 9 months [1]. These are formulation and pharmacokinetic comparisons; the evidence block does not report their results.

Cagrilintide and comparative efficacy across advanced anti-obesity medications

A network meta-analysis examined the comparative efficacy and safety of tirzepatide, semaglutide, cagrilintide and their combination (CagriSema), noting that no direct head-to-head studies had compared all advanced anti-obesity medications [2]. The authors systematically searched PubMed, Scopus and Cochrane Central for randomised clinical trials [2]. The evidence block supplies the background and methods of this analysis but not its pooled estimates, so no comparative effect sizes are reproduced here.

Cagrilintide in amylin-based therapy meta-analysis

A systematic review and meta-analysis evaluated amylin-based obesity therapy, covering cagrilintide as a once-weekly amylin receptor agonist and its fixed-dose combination with semaglutide (CagriSema) [9]. The evidence block describes the scope of the review but does not report its pooled findings.

Cagrilintide-semaglutide in type 2 diabetes: REIMAGINE 1 and REIMAGINE 2

Two phase 3 studies examined the fixed-dose combination of cagrilintide and semaglutide in adults with type 2 diabetes. REIMAGINE 1 was a randomised, double-blind, placebo-controlled phase 3a study in adults with type 2 diabetes inadequately controlled on diet and exercise [10]. REIMAGINE 2 was a double-blind, randomised, controlled phase 3 study comparing cagrilintide-semaglutide with semaglutide or cagrilintide in people with type 2 diabetes [11]. A further commentary describes cagrilintide-semaglutide as a new option for patients with type 2 diabetes [12]. The evidence block does not include the numerical results of these studies.

Cagrilintide and documentation expectations for laboratory sourcing

For research-supply purposes, the documentation that accompanies a cagrilintide lot is the practical equivalent of the identifiers above: a certificate of analysis stating identity, purity and the analytical methods used, plus a batch or lot number that allows the material to be traced. Because the evidence block does not provide a sequence, formula or molecular weight for cagrilintide, identity confirmation in a laboratory setting rests on the supplier's analytical documentation rather than on values reproduced from this page. The clinical record summarised here — animal and cross-species atlas work [3], single-dose pharmacokinetic studies in participants with renal or hepatic impairment [4], and registered studies in people with overweight or obesity [1][5][6][7][8] — describes the research context in which the compound is studied, not a specification for supplied material.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is medical advice. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp